{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:11:00Z","timestamp":1777183860479,"version":"3.51.4"},"reference-count":23,"publisher":"Tsinghua University Press","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.26599\/1671-5411.2025.07.004","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:52:07Z","timestamp":1756713127000},"page":"615-624","source":"Crossref","is-referenced-by-count":2,"title":["Study design and rationale of the TXL-CAP trial: a randomized, double-blind, placebo-controlled, multicenter clinical trial assessing the effect of Tongxinluo capsules on the stability of coronary atherosclerotic plaques"],"prefix":"10.26599","volume":"22","author":[{"given":"Mei","family":"NI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"TI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"QI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayue Darrel","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"YAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Hua","family":"JIA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Li","family":"BU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11138","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/CIRCRESAHA.118.311098","article-title":"Reassessing the mechanisms of acute coronary syndromes","volume":"124","author":"P Libby","year":"2019","unstructured":"P Libby. Reassessing the mechanisms of acute coronary syndromes. 2019, 124: 150-160.","journal-title":"Circ Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1161\/CIRCRESAHA.115.306471","article-title":"From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk","volume":"118","author":"MD Shapiro","year":"2016","unstructured":"MD Shapiro. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk. 2016, 118: 732-749.","journal-title":"Circ Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1093\/eurheartj\/ehl196","article-title":"The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004","volume":"27","author":"L Mandelzweig","year":"2006","unstructured":"L Mandelzweig. The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. 2006, 27: 2285-2293.","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.14797\/mdcj-12-3-152","article-title":"Targeted delivery of shear stress-inducible micrornas by nanoparticles to prevent vulnerable atherosclerotic lesions","volume":"12","author":"WT Wong","year":"2016","unstructured":"WT Wong. Targeted delivery of shear stress-inducible micrornas by nanoparticles to prevent vulnerable atherosclerotic lesions. 2016, 12: 152-156.","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"CD004474","DOI":"10.1002\/14651858.CD004474.pub2","article-title":"Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris","volume":"2006","author":"T Wu","year":"2006","unstructured":"T Wu. Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris. 2006, 2006: CD004474.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3389\/fphar.2018.00830","article-title":"Potential effectiveness of chinese patent medicine tongxinluo capsule for secondary prevention after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"M Li","year":"2018","unstructured":"M Li. Potential effectiveness of chinese patent medicine tongxinluo capsule for secondary prevention after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. 2018, 9: 830.","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010237.pub2","author":"","unstructured":"","journal-title":"null"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jep.2009.04.009","article-title":"Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model","volume":"124","author":"WQ Chen","year":"2009","unstructured":"WQ Chen. Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model. 2009, 124: 103-110.","journal-title":"J Ethnopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"H2004","DOI":"10.1152\/ajpheart.00208.2009","article-title":"Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy","volume":"297","author":"L Zhang","year":"2009","unstructured":"L Zhang. Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy. 2009, 297: H2004-H2014.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"805266","DOI":"10.3389\/fphar.2022.805266","article-title":"Tongxinluo may alleviate inflammation and improve the stability of atherosclerotic plaques by changing the intestinal flora","volume":"13","author":"Y Qi","year":"2022","unstructured":"Y Qi. Tongxinluo may alleviate inflammation and improve the stability of atherosclerotic plaques by changing the intestinal flora. 2022, 13: 805266.","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.amjcard.2013.10.038","article-title":"Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe","volume":"113","author":"M Habara","year":"2014","unstructured":"M Habara. Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe. 2014, 113: 580-587.","journal-title":"Am J Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"M Roffi","year":"2016","unstructured":"M Roffi. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). 2016, 37: 267-315.","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/0002-9149(94)90555-X","article-title":"Monitoring the quality of life in patients with coronary artery disease","volume":"74","author":"JA Spertus","year":"1994","unstructured":"JA Spertus. Monitoring the quality of life in patients with coronary artery disease. 1994, 74: 1240-1244.","journal-title":"Am J Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1161\/01.CIR.0000159354.43778.69","article-title":"In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography","volume":"111","author":"IK Jang","year":"2005","unstructured":"IK Jang. In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. 2005, 111: 1551-1555.","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jacc.2007.04.082","article-title":"Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy","volume":"50","author":"T Kubo","year":"2007","unstructured":"T Kubo. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. 2007, 50: 933-939.","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1038\/s41598-019-41118-z","article-title":"Carotid artery plaque intervention with Tongxinluo capsule (CAPITAL): A multicenter randomized double-blind parallel-group placebo-controlled study","volume":"9","author":"M Zhang","year":"2019","unstructured":"M Zhang. Carotid artery plaque intervention with Tongxinluo capsule (CAPITAL): A multicenter randomized double-blind parallel-group placebo-controlled study. 2019, 9: 4545.","journal-title":"Sci Rep"},{"key":"ref18","first-page":"2858","article-title":"No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: a randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT Trial)","volume":"123","author":"HT Zhang","year":"2010","unstructured":"HT Zhang. No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: a randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT Trial). 2010, 123: 2858-2864.","journal-title":"Chin Med J (Engl)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"673193","DOI":"10.1155\/2013\/673193","article-title":"Evaluation of the add-on effect of chinese patent medicine for patients with stable or unstable angina: a systematic review and meta-analysis","volume":"2013","author":"C Mao","year":"2013","unstructured":"C Mao. Evaluation of the add-on effect of chinese patent medicine for patients with stable or unstable angina: a systematic review and meta-analysis. 2013, 2013: 673193.","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.3892\/mmr.2016.5675","article-title":"Effects of tongxinluo on angiogenesis in the carotid adventitia of hyperlipidemic rabbits","volume":"14","author":"J Zhou","year":"2016","unstructured":"J Zhou. Effects of tongxinluo on angiogenesis in the carotid adventitia of hyperlipidemic rabbits. 2016, 14: 3832-3840.","journal-title":"Mol Med Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"108767","DOI":"10.1016\/j.biopha.2019.108767","article-title":"Tongxinluo may stabilize atherosclerotic plaque via multiple mechanisms scanning by genechip","volume":"113","author":"J Ma","year":"2019","unstructured":"J Ma. Tongxinluo may stabilize atherosclerotic plaque via multiple mechanisms scanning by genechip. 2019, 113: 108767.","journal-title":"Biomed Pharmacother"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jcmg.2014.12.005","article-title":"OCT for the identification of vulnerable plaque in acute coronary syndrome","volume":"8","author":"H Sinclair","year":"2015","unstructured":"H Sinclair. OCT for the identification of vulnerable plaque in acute coronary syndrome. 2015, 8: 198-209.","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/ehjci\/jev283","article-title":"Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis","volume":"17","author":"M Iannaccone","year":"2016","unstructured":"M Iannaccone. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. 2016, 17: 1128-37.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s10554-018-1384-3","article-title":"A review in enormity of OCT and its enduring understanding of vulnerable plaque in coronary bifurcation lesion","volume":"34","author":"R Shrestha","year":"2018","unstructured":"R Shrestha. A review in enormity of OCT and its enduring understanding of vulnerable plaque in coronary bifurcation lesion. 2018, 34: 1679-1684.","journal-title":"Int J Cardiovasc Imaging"}],"container-title":["Journal of Geriatric Cardiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:52:08Z","timestamp":1756713128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciopen.com\/article\/10.26599\/1671-5411.2025.07.004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.26599\/1671-5411.2025.07.004","relation":{},"ISSN":["1671-5411"],"issn-type":[{"value":"1671-5411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}